Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept weight-banded dosing extension in PAH
NCT06925750Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- May 2025
- Primary completion
- Jun 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 19
01
Overview
A Phase 2 trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Merck & Co.. Started May 2025; status: active, not recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06925750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06925750.